Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses ddRNAi as Part of Infringement Settlement with Benitec

NEW YORK, August 11 (GenomeWeb News) - Benitec today said that it has settled a patent infringement case against Ambion, and that Ambion has taken a world-wide nonexclusive license to make and sell ddRNAi (DNA-directed RNAi) -based products as part of the settlement agreement.


Benitec said that the settlement "completely resolves all claims and counterclaims" asserted in a patent infringement dispute that began when the company filed suit against Ambion in March


Financial details of Ambion's licensing agreement were not disclosed.


Benitec has also accused two other firms -- Nucleonics and Genscript -- of infringing Benitec's ddRNAi patent, US Patent No. 6,573,099, entitled "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene." Benitec did not provide information on the status of these lawsuits.  


Benitec currently holds seven issued patents in five jurisdictions, including the US, UK, and Australia, covering RNAi in mammalian cells. The company said that an additional 65 RNAi-based patent applications are in "advanced stages of prosecution" in 14 other jurisdictions.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.